Aarkstore Enterprise: May 2015

Thursday, May 21, 2015

Aarkstore - Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023”. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

Taiho Pharmaceutical’s Lonsurf (TAS-102) is an oral nucleoside antitumor drug which launched in 2014 for the treatment of chemotherapy-refractive metastatic CRC in Japan. In May 2014, Taiho Pharmaceutical announced that the Phase III RECOURSE trial met its primary outcome of OS and that the company is preparing for regulatory submission in the US and Europe. In October 2014, Taiho announced that Lonsurf has received FDA Fast-Track designation and had initiated rolling NDA submission. This positive outcome follows the announcement in March 2014 that Lonsurf had gained regulatory approval for the treatment of recurrent unresectable locally advanced or metastatic CRC in Japan based on Phase II data.

Scope

- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Lonsurf including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Lonsurf for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Lonsurf performance
- Obtain sales forecast for Lonsurf from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

Order full Report with TOC and Sample page visit:

http://www.aarkstore.com/healthcare/87979/lonsurf-colorectal-cancer-forecast-and-market-analysis-to-2023

Related Market Research reports: Healthcare Market Research Reports

About Aarkstore Enterprise

Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.

Contact Details:

Aarkstore Enterprise
Phone: +91 9987295242 / 022-27564953
Email: enquiry@aarkstore.com
Our Website: http://www.aarkstore.com
Our Blog : http://www.aarkstore.com/blog/
Latest News : http://www.aarkstore.com/news
Facebook: https://www.facebook.com/aarkstoredotcom

Aarkstore - Dengue Global Clinical Trials Review, H1, 2013

Summary

GlobalDatas clinical trial report, “Dengue Global Clinical Trials Review, H1, 2013" provides data on the Dengue clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dengue. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Dengue. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Order full Report with TOC and Sample page visit:

http://www.aarkstore.com/pharmaceuticals-healthcare/118380/dengue-global-clinical-trials-review-h1-2013

Related Market Research reports: Healthcare Market Research Reports

About Aarkstore Enterprise

Contact Details:

Aarkstore - CountryFocus Healthcare, Regulatory and Reimbursement Landscape – Denmark

Summary

GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Denmark". The report is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landscape in Denmark. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.

Denmark’s population in 2013 was approximately 5.6 million, having grown at a Compound Annual Growth Rate (CAGR) of 0.5% from 2008. Denmark has a national health insurance scheme, which ensures that all of its residents have access to treatment and health services, regardless of age, income and health. In 2013, the government spent approximately $1.5 trillion on R&D and exported approximately $1.6 trillion of pharmaceutical products. The pharmaceutical market was worth $3.9 billion in 2008 and is projected to reach $3.0 billion by 2020, declining at a CAGR of 2.2%. Although the pharmaceutical market steadily increased in local currency terms between 2008 and 2013, it decreased in US dollar terms, owing to currency devaluation. The medical device market was valued at $1.3 billion in 2008 and is projected to grow at a CAGR of 4.8% to $2.3 billion in 2020, primarily attributed to -
- An increasingly elderly population
- Universal health coverage
- Government initiatives

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Denmark, and includes -
- An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
- Profiles and SWOT analyses of the major players in the pharmaceutical market: Takeda, Novo Nordisk, Lundbeck, Leopharma and Orifarm; and profiles and SWOT analyses of the major players in the medical device market: Siemens Healthcare, Essilor International, Johnson & Johnson Vision Care, Roche and Medtronic
- A review of the reimbursement and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices
- Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
- An overview of the opportunities for and challenges to growth in the healthcare market

Reasons to buy

This report will enhance your decision-making capability by allowing you to -
- Develop business strategies by understanding the trends shaping and driving Denmark’s healthcare market
- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to affect Denmark’s healthcare market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investment, and strategic partnerships
- Identify, understand, and capitalize on the opportunities and challenges in Denmark’s healthcare market

Order full Report with TOC and Sample page visit:

http://www.aarkstore.com/pharmaceuticals-healthcare/79435/countryfocus-healthcare-regulatory-and-reimbursement-landscape-denmark

Related Market Research reports: Healthcare Market Research Reports

About Aarkstore Enterprise

Contact Details:

Aarkstore - CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - US

Summary

GlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - US”. The report is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landscape in the US. It identifies key trends in the country’s healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical devices markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.

The population of the US in 2013 amounted to 316.1 million, having grown at a Compound Annual Growth Rate (CAGR) of 0.8% from 2008. The country’s increasingly elderly population and corresponding increase in the incidence of chronic diseases will help to boost the growth of the pharmaceutical market, which was worth $326.9 billion in 2008, a value that is expected to have reached $548.4 billion by 2020 at a CAGR of 4.4%. Approximately 86.6% of the US population has healthcare coverage, which has helped to create an efficient healthcare system. New initiatives taken by the Food and Drug Administration (FDA) have strengthened the review and approval process. The value of the US medical device market was $116.2 billion in 2008, and is expected to register a CAGR of 5.0% to reach an estimated $209.7 billion in 2020.

These growth trends can be primarily attributed to -
- Sedentary lifestyles, leading to a high chronic disease burden
- High public healthcare expenditure by the Centers for Medicare and Medicaid Services (CMS)
- Increased R&D expenditure
- Easily accessible diagnostic technologies

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in the US, and includes -
- An overview of the pharmaceutical and medical device markets, including market size, segmentation, and key drivers and barriers
- Profiles and SWOT analyses of the major players in the pharmaceuticals market: Pfizer, Merck, Novartis, Sanofi and Abbott; and profiles and SWOT analyses of the major players in the medical device market: Medtronic, DePuy, Siemens Healthcare, Abbott Laboratories, and Stryker
- Insightful review of the reimbursement and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies and the approval processes for new drugs and medical devices
- Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
- An overview of the opportunities for and challenges to growth in the healthcare market

Reasons to buy

This report will enhance your decision-making capability by allowing you to -
- Develop business strategies by understanding the trends shaping and driving the US healthcare market
- Drive revenue by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to affect the US healthcare market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investment, and strategic partnerships
- Identify, understand, and capitalize on the opportunities and challenges in the US healthcare market

Order full Report with TOC and Sample page visit:

http://www.aarkstore.com/pharmaceuticals-healthcare/106875/countryfocus-healthcare-regulatory-and-reimbursement-landscape-us

Related Market Research reports: Healthcare Market Research Reports

About Aarkstore Enterprise

Contact Details:

Aarkstore - PharmaLeaders: CRO Benchmark Report - Financial Performance Benchmarking & Competitive Landscape Assessment of Leading CROs

Summary

The CRO Benchmark Report applies GlobalDatas proprietary ranking methodology to compare the competitive positions of 11 leading CRO companies on 17 financial metrics. These companies are analyzed based on financial performance, cost-containment, capital structure and firm utilization to illustrate the different strategies these companies are using to increase value for their shareholders. Throughout the report, GlobalDatas Industry Dynamics Team provides you with expert insight, expanding on each of the metrics discussed. In addition to the financial metrics, this report discusses trends impacting the CRO marketplace, along with partnering and acquisition activity, and operations strategy. This report also provides drill-down analyses of three service lines and four geographies examining each of these segments revenue and growth leaders, and business development strategies. Lastly, this report provides GlobalDatas outlook on the CRO sector and each companys future competitive position.

Highlights

The CRO market is highly fragmented comprised of some 1,000 individual companies, most of which are privately owned. These companies vary significantly in size and breadth of services - from a four person bioanalysis research lab in Thailand to companies like Quintiles and Covance which have tens of thousands of employees in over 100 countries across the globe. GlobalData identified 11 CROs to apply its benchmarking methodology providing a foundation for strategic discussion and analysis. GlobalDatas coverage examines these CROs from a unique company-centric lens - combining financial performance and resources allocation with partnering activity and regional developments to assess a companys overall strategy. This type of coverage is unlike any other analysis available, and delivers a consistent view into the evolution of these companies corporate growth. We also covered some 30 other privately-held CROs to give our analysis more specificity and granularity.

Key Questions Answered

What specific strategies are these CROs employing to gain market share?
What drivers accounted for the revenue growth for the company over the past year?
Which trends will affect the CRO marketplace over the next few years?
What particular services or capabilities are my competitors developing?
Who are the revenue and growth leaders in each service line and geography?
What specific business development activities are taking place, in terms of partnerships or M&A?
How are CROs growing their physical infrastructures and human resources to better serve the needs of their customers?
What region-specific operations and capabilities are CROs adding to gain share in emerging markets?

Scope

Analysis of the key drivers and trends shaping the global CRO market; including biologics manufacturing, emerging markets, and eClinical technologies
A deep dive into the synergies behind partnering and acquisition activity
Discussion of business line and regional segment strategies
Assessments of company financials by revenue, margin, expense and capital structure
Firm utilization, resources management, and efficiency metrics
Leadership/management changes

Reasons to buy

Analyze and track the strategies that these CROs are using to gain share in the increasingly competitive market
Understand the underlying financial metrics that differentiate certain companies from the pack in terms of growth and profitability, spending and asset structure
Organize your sales and marketing strategy to identify companies with proprietary technologies to maximize opportunities for strategic investment or partnerships
Use this information as an independent source for your due diligence and transaction strategy

Order full Report with TOC and Sample page visit:

http://www.aarkstore.com/pharmaceuticals-healthcare/109500/pharmaleaders-cro-benchmark-report-financial-performance-benchmarking-competitive-landscape-assessment-of-leading-cros

Related Market Research reports: Healthcare Market Research Reports

About Aarkstore Enterprise

Contact Details:

Aarkstore - The Market for Stem Cell Biobanking and Storage - Size, Segments, and Trends

Summary

Purpose of Report: The purpose of this global strategic report is to prepare executives, company management, and industry investors with the data and knowledge necessary to make informed, educated decisions about commercial opportunities within the stem cell biobanking market.

This global strategic report is produced for:

• Executives of Industrial-Scale Biobanks
• Management of Stem Cell Product Companies
• Management of Stem Cell Therapy Companies
• Biobanking Industry Investors

It is designed to increase your efficiency and effectiveness in:

1. Effectively pricing stem cell biobanking services
2. Increasing revenue from stem cell biobanking services
3. Identifying new or adjunct stem cell biobanking services to offer
4. Identifying current market leaders within the stem cell biobanking market
5. Characterizing the competitive environment for the stem cell biobanking market
6. Identifying threats and opportunities within the stem cell biobanking market
7. Acquiring greater market within the stem cell biobanking market
8. Making intelligent investment decisions within the stem cell biobanking market

OVERVIEW

Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into mature cell types. Stem cells are still a relatively new discovery, as the first mouse embryonic stem cells were derived from embryos in 1981, but it was not until 1995 that the first culturing of embryonic stem cells from non-human primates occurred. Induced pluripotent stem cells were not produced until 2006. As a result of these discoveries, stem cells can now be derived at various points during the life cycles.

The following are stages during which stem cells can be derived:

• Embryonic stem cells, derived from blastocysts
• Fetal stem cells, obtained from fetuses
• Post-natal stem cells derived from newborn tissues, including cord blood stem cells from umbilical tissue
• Adult stem cells found in adult tissues, including hematopoietic stem cells, mesenchymal stem cells, and neural stem cells
• Induced pluripotent stem cells, reprogrammed from adult cells
• Cancer stem cells, which give rise to clonal populations of cells that form tumors or disperse in the body
• And more

Forces Driving the Stem Cell Biobanking Market

Stem cell research and experimentation is largely driven by the unique ability of stem cells to divide and replicate repeatedly. In addition, their “unspecialized” nature allows them to differentiate into a wide variety of specialized cell types. In a developing embryo, stem cells can differentiate into all of the specialized embryonic tissues. In adult organisms, stem and progenitor cells act as a repair system for the body, replenishing specialized cells.

Therefore, the possibilities arising from these characteristics have resulted in great commercial interest, with potential applications ranging from the use of stem cells in reversal and treatment of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, and more. Huntington’s disease, Parkinson’s disease, and spinal cord injuries are examples of conditions for which clinical applications involving stem cells could offer benefits in halting or even reversing adverse effects.
However, to have stem cells easily accessible for research purposes and clinical applications requires them to be preserved in stable, temperature controlled conditions. For this reason, a substantial market has evolved for the biobanking of tissues containing stem cell populations and the storage of stem cells themselves.

Stem Cell Biobanking Market

Stem cell biobanking is the cryogenic storage of stem cells, or biological samples containing stem cells, for later use. The market for these services is known as the “Stem Cell Biobanking Market.” Because stem cell biobanking often involves the long-term storage of stem cell samples, the market is sometimes is also known as the “Stem Cell Storage Market.” For purposes of this analysis, these two terms are considered to be synonymous. A definition of this market is provided below.

Stem Cell Biobanking Market:

The stem cell biobanking market is defined as the total annual revenue derived from the storage of:

1. Stem cell lines and their derivatives
2. All biological samples that were collected specifically because they contain stem cell populations (e.g. cord blood, adipose tissue, and more)

This report aims to understand and characterize the competitive environment for the stem cell biobanking market. As such, the research is focused on identifying leading participants in the stem cell storage market, distinguishing their business model, and exploring their relative market share.
Currently, the four leading providers of biobanking services are: Fisher Bioservices, Biostorage Technologies, EPL Archives, and Precision Bioservices. All four companies store millions of biological samples (15 million by Precision Bioservices, up to 170 million by Fisher Bioservices) and provide a diverse set of biobanking services. All but Precision Biosciences are multi-national companies with both U.S. and European operations. Because each company has large market share within the stem cell biobanking market, they are explored in detail within this report.

However, there are also companies specializing exclusively in stem cell storage. In one landmark event, Cellular Dynamics International (CDI) and the Coriell Institute for Medical Research announced receiving multi-million dollar grants from the California Institute for Regenerative Medicine (CIRM) for the creation of induced pluripotent stem cell (iPSC) lines from 3,000 healthy and diseased donors. CIRM awarded CDI $16 million to create three iPSC lines for each of 3,000 healthy and diseased donors and awarded the Coriell Institute $10 million to set up and biobank the iPSC lines. The result will be thecreation of the world’s largest human iPSC bank, an incredible feat.

This iPSC biobank is one example of the expanding market for stem cell biobanking services. Because the goal of stem cell biobanking is to create a repository of stem cell specimens – including source tissue from which stem cells can be derived, differentiated cell types produced, and disease-specific cell lines created – large-scale stem cell biobanks provide researchers with the opportunity to investigate a diverse range of conditions using stem cells derived from both healthy and diseased donors. Importantly, biobanks can greatly expand the capacity for global research and collaboration.

Key report findings include:

• Current Size of the Stem Cell Biobanking Market
• Trailing 5-Year Market Size Data (2011-2015)
• 5-year Market Size Projections (2016-2020)
• Market Segmentation
• Market Share by Segment
• Key Industry Leaders
• Detailed Competitive Environment Analysis
• Analysis of Stem Cell Storage Applications (End-Uses)
• Number of Stem Cell Samples Banked, by Industry Leader
• Identification of Opportunities within the Stem Cell Biobanking Market
• And Much More

Competing within the stem cell biobanking market can involve complicated and confusing decisions, but it doesn’t need to. Claim this global strategic report to quickly understand current and future trends within the stem cell biobanking marketplace, identify opportunities by market segment, and derive more revenue from your stem cell biobanking products and services.

Order full Report with TOC and Sample page visit:

http://www.aarkstore.com/healthcare/118592/the-market-for-stem-cell-biobanking-and-storage-size-segments-and-trends

Related Market Research reports: Healthcare Market Research Reports

About Aarkstore Enterprise

Contact Details:

Friday, May 15, 2015

Aarkstore - Frontier Pharma: Alzheimers Disease - Identifying and Commercializing First-in-Class Innovation

Summary

Large and Innovative Pipeline

The active Alzheimer’s Disease (AD) pipeline is populated with 583 products, with a highly diverse range of molecular targets. GBI Research analysis revealed a high degree of innovation in this indication, with 46% of the pipeline being first-in-class products, acting on over 40 first-in-class molecular targets. In addition, the pipeline is characterized by the strong presence of therapies that target multiple components implicated in the amyloid cascade, several molecular targets of which are known to trigger familial AD. Given that the currently approved therapies for AD are limited to acetylcholinesterase inhibitors and glutamate receptor antagonists, the pipeline offers a broad range of treatment options that may possess disease-modifying properties. However, evaluation of the Preclinical and clinical evidence for their therapeutic potential reveals that the novelty of the molecular target is not sufficient to effectively reduce the rate of AD progression in human patients.

Disease-Modifying Therapies Show Promise in Early-Stage Development

Programs undergoing Preclinical development exhibit diverse disease-modifying mechanisms of action, and many represent strong alternatives to targets with a direct role in the amyloid and tau processes due to their roles in promoting neuronal survival and plasticity, a process critical to memory and cognition. Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) are considered promising targets in AD, primarily due to their potency in exhibiting significant neuroprotective effects in Preclinical studies. Members of the caspase-mediated apoptotic cascade also show therapeutic potential, as early investigations have revealed an ability to modulate molecular mechanisms underlying synaptic plasticity in animal models, which translates into amelioration of behavioral deficits. Thus, growing insights into disease-causing processes in AD are being translated into a growing population of innovative therapeutic targets, as reflected in the highly innovative pipeline.

The merits of novel molecular targets depend largely on the body of Preclinical evidence underpinning their relevance to AD pathology. Many endpoints in Preclinical investigations focus on amelioration of amyloid burden and tau pathology, as well as cognitive performance in animal model systems. Based on these assessment criteria, it appears that programs targeting the amyloid cascade, tau pathology, and the promotion of neuronal survival and plasticity all demonstrate promising efficacy profiles. Other first-in-class targets that are less directly aligned to these three processes may not be able to confer disease-modifying properties and therefore lack clinical and commercial potential.

Active Deals Landscape with Numerous Investment Opportunities

The AD deals landscape has been highly active over the past eight years, with 83 licensing agreements and 103 co-development deals. Overall, non-first-in-class programs tend to have lower valuations than first-in-class programs across all stages of drug development, which highlights their commercial attractiveness, even in early-stage development. Although first-in-class programs are associated with greater risk, they have more potential to revolutionize or improve therapeutic options, meaning that identifying promising first-in-class compounds early in development offers the greatest potential commercial benefit to pharmaceutical companies.

With 153 first-in-class products that are currently in development having not yet been involved in a licensing or co-development deal, there are numerous opportunities for in-licensing or co-development in this indication.

Scope

The report covers and includes -
- A brief introduction to AD, including symptoms, pathophysiology, and overview of pharmacotherapy and treatment algorithms
- The changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline
- A comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target
- Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews of novel molecular targets
- Assessment of the licensing and co-development deal landscape for AD therapies and benchmarking of deals involving first-in-class versus non-first-in-class-products

Reasons to buy

The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to -
- Understand the focal shifts in molecular targets in the AD pipeline
- Understand the distribution of pipeline programs by phase of development, molecule type and molecular target
- Access a scientific and clinical analysis of first-in-class developmental programs for AD, benchmarked against non-first-in-class targets
- Access a list of the first-in-class therapies potentially open to deal-making opportunities

Browse complete Report on:

http://www.aarkstore.com/pharmaceuticals-healthcare/105777/frontier-pharma-alzheimers-disease-identifying-and-commercializing-first-in-class-innovation

Related Market Research reports: Pharmaceuticals & Healthcare Market Research Reports

About Aarkstore Enterprise

Contact Details:

Aarkstore - MediPoint: Nuclear Imaging - PET and SPECT Equipment - Global Analysis and Market Forecasts

Summary

This Market Research Report “MediPoint: Nuclear Imaging - PET and SPECT Equipment - Global Analysis and Market Forecasts” examines how new technologies can emerge in the face of economic pressures that may affect the demand for nuclear imaging, and how healthcare reforms are impacting nuclear medicine.

The advent of hybrid imaging has enabled PET/CT imaging to undergo explosive growth. However, this has been at the cost of an increased demand on struggling healthcare budgets

PET and SPECT imaging are well established techniques within nuclear imaging, and are the main focus of this report

PET imaging uses Positron Emitting radioactive tracers with a short half life, to image metabolically active organs

PET combined with CT allows precise anatomical imaging of the body, identifying diseased areas depending upon the tracer used

PET/CT is most often used for cancer diagnosis

PET/MRI is a new technique that was introduced to reduce patient exposure to radiation

PET only systems are now generally considered obsolete, due to the superior imaging quality of PET/CT

SPECT imaging uses Gamma Emitting radioactive tracers with a longer half life, to image molecular processes in the body

SPECT and SPECT/CT are most often used in cardiology studies

The SPECT and SPECT/CT market is a bigger market than the PET, PET/CT and PET/MRI, because the instruments have been in longer use, are cheaper, and have become the common technique for a wide range of indications

Physicians believe more and more SPECT procedures will be replaced by PET procedures

New developments in hybrid nuclear imaging promise to further increase the utility of hybrid nuclear imaging, while significantly improving patient cost-savings and safety, through reduced need for repeat examinations.

This report focuses on the current and future industry trends within the nuclear medicine market, as well as discussing the promising pipeline products, and assessing the competitive landscape.

Highlights

Key Questions Answered

- What is the current and future nuclear imaging market outlook in the developed and emerging markets? What trends are affecting the global market for both SPECT and PET imaging systems?
- Which are the key, high growth markets that manufacturers should seek to expand into? What are the types of products that are most likely to succeed?
- How many Nuclear Imaging Procedures are carried out in each of the 10 Major Markets? What does this imply for instrument adoption rates?
- What are the major unmet needs in nuclear imaging? In which areas can manufacturers help meet that need?
- What factors most influence a physician or hospital in the purchase of new nuclear imaging equipment? How much can a physician influence purchasing decisions?
- How will reimbursement changes will affect nuclear imaging. How has the Affordable Care Act affected nuclear imaging? How will it affect it in the future?
- How well are new paradigms in nuclear imaging perceived? What motivates companies to develop a new nuclear imaging modality; physician demand or legislative requirement?

Key Findings

- Nuclear Imaging is a moderately growing market, with a CAGR of 3.3% for the period to 2020
- PET/CT, SPECT, SPECT/CT and Scinitgraphy are the major techniques in nuclear imaging
- US dominates the world market for nuclear imaging equipment
- US will see lowest growth in nuclear imaging equipment thanks to reimbursement pressures
- Japan and China will present the greatest opportunities for growth, with respective market shares increasing by 75% and almost 100% during the forecasted period
- BIC nations will experience the highest growth rates in nuclear imaging equipment during the forecast period
- Non-PET nuclear imaging procedures in the developed markets (US, 5EU, Japan) likely overall to fall during forecast period, as a result of increasing reimbursement pressures and new technologies
- PET imaging procedures in all markets likely to increase during the forecast period, despite reimbursement pressures, due to increased number of indications

Scope

- Overview of Nuclear Imaging, including core technologies, estimated procedure trends and disease overview.
- Current and Future Players Companies involved in the space with portfolio assessment and SWOT analysis.
- Pipeline analysis: Comprehensive data split across different stages of development, emerging trends and nuclear imaging devices in development
- Annualized total nuclear imaging equipment market revenue for SPECT, SPECT/CT, PET, PET/CT and PET/MRI, and procedure data for 2012-2013, and forecast for seven years to 2020
- Other Key topics covered include identification of unmet needs, implications for the nuclear imaging market and how they may be overcome in the near future, reimbursement and regulatory considerations, evaluating market access for each region covered in the report
- Analysis of the market opportunities in the Nuclear Imaging market, in addition to Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline in the fields of PET/CT, PET/MRI and SPECT/CT.
- Develop business strategies by understanding the trends shaping and driving the nuclear imaging market
- Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the nuclear imaging market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Track device sales in the global and country-specific nuclear imaging markets from 2012-2020
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships

Browse complete Report on:

http://www.aarkstore.com/general-medical-devices/84788/medipoint-nuclear-imaging-pet-and-spect-equipment-global-analysis-and-market-forecasts

Related Market Research reports: General Medical Devices Market Research Reports

About Aarkstore Enterprise

Contact Details:

Aarkstore - Global Propylene Industry On-Purpose Technologies to Gain Prominence

Summary

GlobalData, the industry analysis specialist, has released its latest research, “Global Propylene Industry – On-Purpose Technologies to Gain Prominence”. The study comes from the company’s oil and gas research group and provides market analysis of the global propylene industry, highlighting major features of the industry.

The Market Research Report gives the historic and forecast, market size, demand and production figures by region. It covers all five regions that include Asia-Pacific, Europe, North America, South America, and Middle East and Africa. The report has been built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s research team of industry experts.

The global propylene industry is witnessing a change in the feedstock scenario in various parts of the world. In North America, propylene supply from steam crackers is expected to decrease in coming years as abundant and inexpensive natural gas liquids (NGLs) feedstock form shale gas is slowly replacing heavy feedstock in steam crackers. Persistently high crude oil price is also discouraging the use of naphtha China and Europe. To cope with the changing feedstock scenario and high crude oil prices many producers are embracing on-purpose propylene technologies which produce high quantities of propylene by using alternative feedstocks such as NGLs and coal. Use of these technologies is being witnessed mostly in Asia-Pacific and North America. In Asia-Pacific, more than 50% of new capacity will come from on-purpose technologies while in North America, 100% of the new capacity will come from on-purpose technologies. With the increasing demand for propylene and uncertainty of propylene supply from stream crackers, the use of on-purpose technology will continue to increase in the future.

Scope

The report provides in-depth analysis of the demand and supply dynamics of the global propylene industry. Its scope includes –

– Historic and forecast global propylene capacity by region
– Propylene planned plants details
– Global propylene capacity by feedstock
– Capacity share of the major propylene producers in the world
– Historic and forecast propylene market size, demand and production by region
– Global propylene demand by end-use sectors
– Propylene price forecast by region
– Company profile of three largest company in the propylene industry

Reasons to buy

The report will enhance your decision-making capability by allowing you to –

– Understand the key trends and challenges in the global propylene industry
– Understand the regional propylene supply scenario
– Understand the current and likely future competitive scenario
– Identify opportunities in the global propylene industry with the help of specific insights on demand and supply dynamics
– Increase future revenues and profitability with the help of insights into future opportunities and critical success factors in the global propylene industry

Browse complete Report on:

http://www.aarkstore.com/chemicals/117603/global-propylene-industry-on-purpose-technologies-to-gain-prominence

Related Market Research reports: Chemicals Market Research Reports

About Aarkstore Enterprise

Contact Details:

Aarkstore - Gas Processing Industry Outlook in Europe, 2014

Summary

“Gas Processing Industry Outlook in Europe, 2014 - Investment Opportunities, Analysis and Forecasts of All Active and Planned Gas Processing Plants in Europe” is a comprehensive report on gas processing industry in Europe. It provides in-depth asset details of all active and planned plants in the region. Details include operator name, start year, process/conditioning methods and processing capacity. Planned plants as announced by the companies have been included in the report. The research gives information on the market shares of major gas processing companies in Europe. The report also provides profiles of three major gas processing operators in Europe.

Scope

- The report provides detailed information and analysis on gas processing plants in Europe.
- The research work includes country wise processing capacities of active and planned processing plants in the region
- Information on gas processing capacity of top five companies is provided
- Profiles of three major companies operating in the industry are also included in the report.

Reasons to buy

- The report will enhance your decision making capability in a more rapid and time sensitive manner.
- The research will allow you to identify prospective investment targets through a comprehensive update and discussion on processing plants
- Decide on market entry strategies in specific markets with the help of an up-to-date review of all gas processing plant capacities
- Benchmark yourself against major gas processing companies by leveraging on our detailed company analysis.

Browse complete Report on:

http://www.aarkstore.com/energy-power/89554/gas-processing-industry-outlook-in-europe-2014-investment-opportunities-analysis-and-forecasts

Related Market Research reports: Energy & Power Market Research Reports

About Aarkstore Enterprise

Contact Details:

Aarkstore - Smart Grid Policy Handbook 2015

Summary

“Smart Grid Policy Handbook 2015” is the latest policy report from GlobalData. It provides in-depth analysis of smart grid technology policies across major countries in the world: the US, Canada, Mexico, Brazil, the EU, Germany, the UK, France, Spain, Saudi Arabia, South Africa, India, China, Japan, South Korea, Singapore and Australia. Major topics include Advanced Metering Infrastructure (AMI), microgrid, smart cities, net metering, Time of Use (ToU) pricing, communication protocol, Electric Vehicles (EV), and Energy Management Systems.

Scope

The Market Research Report provides comprehensive coverage of key smart grid initiatives and policies for the following countries and regions: the US, Canada, Mexico, Brazil, the EU, Germany, the UK, France, Spain, Saudi Arabia, South Africa, India, China, Japan, South Korea, Singapore and Australia. It covers the following major topics -
- AMI
- Microgrid
- Smart cities
- Net metering
- ToU pricing
- Communication protocol
- Important smart grid agencies
- EV
- EMS

Reasons to buy

The report will enhance your decision-making capability by allowing you to -
- Develop business strategies using specific insights into policy decisions
- Identify opportunities to exploit the smart grid market, as well as the challenges involved
- Compare the level of support for smart grid technologies by country
- Increase future revenue and profitability using insights into future opportunities and critical success factors in the smart grid market

Browse complete Report on:
http://www.aarkstore.com/energy-resources/115979/smart-grid-policy-handbook-2015

Related Market Research reports: Energy & Resources Market Research Reports

About Aarkstore Enterprise

Contact Details:

Tuesday, May 12, 2015

Aarkstore - Molecular Diagnostics in Infectious Disease Testing

Summary

This TriMark Publications report “Molecular Diagnostics in Infectious Disease Testing” describes the specific segment of the in vitro diagnostics market known as molecular diagnostics testing for infectious disease. In the current medical diagnostics market, molecular diagnostics in infectious disease testing offers one of the most promising areas for growth and innovation. The confluence of breakthroughs in genomics and proteomics--along with the development of microarray devices to measure analytes in the blood--has led to this revolutionary market development. Specifically, molecular diagnostics offers the power of advanced analytical techniques to diagnose infectious diseases. Whereas before, the detection of many infectious agents was slow and expensive due to reliance upon culturing methods, researchers are now at the cusp of overcoming such limitations via the use of nucleic acid-mediated molecular diagnostics testing.

The purpose of this report is to describe the emerging field of molecular diagnostics in infectious disease testing. The infectious disease space is the most dominant and profitable sector of molecular diagnostics. Topics covered in this study include: 1) the existing and emerging technologies in the field, 2) the U.S. and global market size for molecular diagnostic products and 3) the profiles of companies that are focusing on the molecular diagnostic sector. The research examines drivers and restraints for sales growth, market share and technical trends. In addition, an in-depth analysis of the competitive situation of prominent market venders is provided with five-year sales forecasts.

Browse complete Report on:

http://www.aarkstore.com/healthcare/35964/molecular-diagnostics-in-infectious-disease-testing

Related Market Research reports: Healthcare Market Research Reports

About Aarkstore Enterprise

Contact Details: